The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer
IntroductionThe ubiquitin-proteasome system (UPS) is an intracellular organelle responsible for targeted protein degradation, which represents a standard therapeutic target for many different human malignancies.Bortezomib, a reversible inhibitor of chymotrypsin-like proteasome activity, was first approved by the FDA in 2003 to treat multiple myelom